lantern pharma inc - LTRN
LTRN
Close Chg Chg %
1.84 -0.07 -3.80%
Open Market
1.77
-0.07 (3.80%)
Volume: 36.72K
Last Updated:
Sep 9, 2026, 10:00 AM EDT
Company Overview: lantern pharma inc - LTRN
LTRN Key Data
| Open $1.82 | Day Range 1.77 - 1.85 |
| 52 Week Range 1.11 - 4.70 | Market Cap $24.42M |
| Shares Outstanding 12.78M | Public Float 9.94M |
| Beta 2.30 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.61 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 142.96K |
LTRN Performance
| 1 Week | -3.41% | ||
| 1 Month | -35.66% | ||
| 3 Months | -52.58% | ||
| 1 Year | -51.96% | ||
| 5 Years | -86.36% |
LTRN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
3
Full Ratings ➔
About lantern pharma inc - LTRN
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
LTRN At a Glance
Lantern Pharma, Inc.
1920 McKinney Avenue
Dallas, Texas 75201
| Phone | 1-972-277-1136 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -17,119,438.00 | |
| Sector | Health Technology | Employees | 16 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
LTRN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.219 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.279 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.003 |
LTRN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,069,964.875 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
LTRN Liquidity
| Current Ratio | 2.40 |
| Quick Ratio | 2.40 |
| Cash Ratio | 2.248 |
LTRN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -93.52 |
| Return on Equity | -123.508 |
| Return on Total Capital | -258.885 |
| Return on Invested Capital | -123.273 |
LTRN Capital Structure
| Total Debt to Total Equity | 1.202 |
| Total Debt to Total Capital | 1.188 |
| Total Debt to Total Assets | 0.711 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Lantern Pharma Inc - LTRN
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 154.68K | 174.84K | 190.49K | 17.28K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 154.68K | 174.84K | 190.49K | 17.28K | |
Depreciation
| 154.68K | 174.84K | 190.49K | 17.28K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +58.78% | +13.03% | +8.95% | -90.93% | |
Gross Income
| (154.68K) | (174.84K) | (190.49K) | (17.28K) | |
Gross Income Growth
| -58.78% | -13.03% | -8.95% | +90.93% | |
Gross Profit Margin
| - | - | - | - | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 14.28M | 17.70M | 22.03M | 17.96M | |
Research & Development
| 8.60M | 11.89M | 16.13M | 11.51M | |
Other SG&A
| 5.68M | 5.81M | 5.90M | 6.45M | |
SGA Growth
| +14.28% | +23.99% | +24.42% | -18.45% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 492.50K | - |
EBIT after Unusual Expense
| (14.93M) | (17.88M) | (22.22M) | (17.98M) | |
Non Operating Income/Expense
| 665.30K | 1.92M | 1.44M | 859.05K | |
Non-Operating Interest Income
| 204.35K | 765.39K | 742.36K | 437.93K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (14.26M) | (15.96M) | (20.78M) | (17.12M) | |
Pretax Income Growth
| -15.34% | -11.93% | -30.20% | +17.62% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (14.26M) | (15.96M) | (20.78M) | (17.12M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (14.26M) | (15.96M) | (20.78M) | (17.12M) | |
Net Income Growth
| -15.34% | -11.93% | -30.20% | +17.62% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (14.26M) | (15.96M) | (20.78M) | (17.12M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (14.26M) | (15.96M) | (20.78M) | (17.12M) | |
EPS (Basic)
| -1.3142 | -1.4722 | -1.9309 | -1.5708 | |
EPS (Basic) Growth
| -15.92% | -12.02% | -31.16% | +18.65% | |
Basic Shares Outstanding
| 10.85M | 10.84M | 10.76M | 10.90M | |
EPS (Diluted)
| -1.3142 | -1.4722 | -1.9309 | -1.5708 | |
EPS (Diluted) Growth
| -15.92% | -12.02% | -31.16% | +18.65% | |
Diluted Shares Outstanding
| 10.85M | 10.84M | 10.76M | 10.90M | |
EBITDA
| (14.28M) | (17.70M) | (22.03M) | (17.96M) | |
EBITDA Growth
| -14.28% | -23.99% | -24.42% | +18.45% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 18.00 | |
| Number of Ratings | 3 | Current Quarters Estimate | -0.35 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -1.63 | |
| Last Quarter’s Earnings | -0.57 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.57 | Next Fiscal Year Estimate | -2.02 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 1 | 1 | 1 | 1 |
| Mean Estimate | -0.35 | -0.41 | -1.63 | -2.02 |
| High Estimates | -0.35 | -0.41 | -1.63 | -2.02 |
| Low Estimate | -0.35 | -0.41 | -1.63 | -2.02 |
| Coefficient of Variance | N/A | N/A | N/A | N/A |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Lantern Pharma Inc - LTRN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Lantern Pharma Inc - LTRN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 14, 2026 | Maria-Luisa Maccecchini Director | 25,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Maria-Luisa Maccecchini Director | 21,152 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Donald Jeffrey Keyser Director | 25,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Donald Jeffrey Keyser Director | 28,844 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | David S. Silberstein Director | 17,307 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | David S. Silberstein Director | 25,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Lee T. Schalop Director | 25,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Lee T. Schalop Director | 18,460 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Vijay Chandru Director | 17,307 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 14, 2026 | Vijay Chandru Director | 25,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 24, 2025 | David R. Margrave Chief Financial Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Sep 24, 2025 | Kishor G. Bhatia Chief Scientific Officer | 17,400 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 24, 2025 | Vijay Chandru Director | 3,200 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 24, 2025 | Vijay Chandru Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Sep 24, 2025 | David R. Margrave Chief Financial Officer | 26,100 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 24, 2025 | David R. Margrave Chief Financial Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Sep 24, 2025 | David R. Margrave Chief Financial Officer | 78,300 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 24, 2025 | Panna L. Sharma President & CEO; Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Sep 24, 2025 | Donald Jeffrey Keyser Director | 3,200 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 24, 2025 | Donald Jeffrey Keyser Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |